{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:14:27Z","timestamp":1779297267717,"version":"3.51.4"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.clim.2020.108395","type":"journal-article","created":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T11:04:41Z","timestamp":1585566281000},"page":"108395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations"],"prefix":"10.1016","volume":"214","author":[{"given":"Elisa","family":"Gremese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Alivernini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo Sean","family":"Ferraccioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianfranco","family":"Ferraccioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2020.108395_bb0005","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1042\/EBC20160017","article-title":"The immune system","volume":"60","author":"Nicholson","year":"2016","journal-title":"Essays Biochem."},{"key":"10.1016\/j.clim.2020.108395_bb0010","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.clinbiochem.2015.05.019","article-title":"Mechanism of immunological tolerance","volume":"49","author":"Waldmann","year":"2016","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.clim.2020.108395_bb0015","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1172\/JCI78089","article-title":"T cells in the control of organ-specific autoimmunity","volume":"125","author":"Bluestone","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2020.108395_bb0020","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Ann. Rev. Immunol."},{"key":"10.1016\/j.clim.2020.108395_bb0025","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.clim.2020.108395_bb0030","doi-asserted-by":"crossref","first-page":"E221","DOI":"10.1073\/pnas.1208573110","article-title":"CTLA-4 controls the thymic development of both conventional and regulatory T cells through modulation of the TCR repertoire","volume":"110","author":"Verhagen","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2020.108395_bb0035","doi-asserted-by":"crossref","first-page":"E2383","DOI":"10.1073\/pnas.1603892113","article-title":"Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood","volume":"113","author":"Klocke","year":"2016","journal-title":"PNAS"},{"key":"10.1016\/j.clim.2020.108395_bb0040","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/intimm\/dxs098","article-title":"PD-1 is a novel regulator of human B- cell activation","volume":"25","author":"Thibult","year":"2013","journal-title":"Int. Immunol."},{"key":"10.1016\/j.clim.2020.108395_bb0045","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Ann.Rev.Immunol."},{"key":"10.1016\/j.clim.2020.108395_bb0050","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-16-0307","article-title":"PD-1 shapes B cells as evildoers in the tumor microenvironment","volume":"6","author":"Ren","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clim.2020.108395_bb0055","article-title":"Immunosuppressive B cells expressing PD-1\/PD-L1 in solid tumors: a mini review","author":"Sun","year":"2020","journal-title":"Quarterly J. Med."},{"key":"10.1016\/j.clim.2020.108395_bb0060","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.molimm.2019.02.009","article-title":"PD-1-expressing B cells suppress CD4+ and CD8+ T cells via PD-1\/PD- L1-dependent pathway","volume":"109","author":"Wang","year":"2019","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.clim.2020.108395_bb0065","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.4049\/jimmunol.1101990","article-title":"Programmed cell death 1 suppresses B-1b cell expansion and long-lived IgG production in response to T cell-independent type 2 antigens","volume":"187","author":"Haas","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2020.108395_bb0070","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.it.2006.02.001","article-title":"The PD-1\u2013PD-L pathway in immunological tolerance","volume":"27","author":"Okazaki","year":"2006","journal-title":"Trends Immunol."},{"key":"10.1016\/j.clim.2020.108395_bb0075","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.immuni.2014.12.005","article-title":"The coinhibitory receptor CTLA-4 controls b cell responses by modulating T follicular helper, T follicular regulatory and T regulatory cells","volume":"41","author":"Sage","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2020.108395_bb0080","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1159\/000480641","article-title":"The systemic activation of programmed death 1-PD-L1 axis protects systemic lupus erythematosus model from nephritis","volume":"46","author":"Liao","year":"2017","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.clim.2020.108395_bb0085","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1093\/rheumatology\/kez228","article-title":"PD-1+CXCR5_CD4+T cells are correlated with the severity of systemic lupus erythematosus","volume":"58","author":"Lin","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clim.2020.108395_bb0090","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s13075-015-0859-z","article-title":"Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways","volume":"17","author":"Liu","year":"2015","journal-title":"Arthritis Res. Ther."},{"issue":"9","key":"10.1016\/j.clim.2020.108395_bb0095","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.3389\/fimmu.2018.02241","article-title":"PD-L1+ Regulatory B Cells are significantly decreased in rheumatoid arthritis patients and increase after successful treatment","volume":"1","author":"Zacca","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2020.108395_bb0100","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s10753-015-0132-2","article-title":"Analysis of programmed death-1 in patients with psoriatic arthritis","volume":"38","author":"Peled","year":"2015","journal-title":"Inflammation"},{"issue":"10","key":"10.1016\/j.clim.2020.108395_bb0105","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.4049\/jimmunol.1302750","article-title":"STAT3, STAT4, NFATc1, and CTCF regulate PD-1 through multiple novel regulatory regions in murine T cells","volume":"192","author":"Austin","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2020.108395_bb0110","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2020.108395_bb0115","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12967-014-0373-0","article-title":"PD-1\/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation","volume":"13","author":"Ji","year":"2015","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.clim.2020.108395_bb0120","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nm.4321","article-title":"Is autoimmunity the Achilles\u2019 heel of cancer immunotherapy?","volume":"27","author":"June","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2020.108395_bb0125","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3389\/fmed.2018.00351","article-title":"Cytokines, chemokines, and other biomarkers of response for check- point inhibitor therapy in skin cancer","volume":"5","author":"Bridge","year":"2018","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.clim.2020.108395_bb0130","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Ann.Rev. Immunol."},{"key":"10.1016\/j.clim.2020.108395_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-380866-0.60002-2","article-title":"DNA methylation and cancer","volume":"70","author":"Kulis","year":"2010","journal-title":"Adv. Genet."},{"key":"10.1016\/j.clim.2020.108395_bb0140","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1073\/pnas.1308362110","article-title":"Dysregulation of PAD4- mediated citrullination of nuclear GSK3b activates TGF-b signaling and induces epithelial-to-mesenchymal transition in breast cancer cells","volume":"110","author":"Stadler","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2020.108395_bb0145","doi-asserted-by":"crossref","DOI":"10.1126\/science.aao4227","article-title":"Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice","volume":"361","author":"Albrengues","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.clim.2020.108395_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191231","article-title":"Citrullinated histone H3 as a novel prognostic blood marker in patients with advanced cancer","volume":"13","author":"Thalin","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2020.108395_bb0155","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1158\/0008-5472.CAN-18-2797","article-title":"Citrullination in cancer","volume":"79","author":"Yuzhalin","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2020.108395_bb0160","first-page":"449","article-title":"Lactate dehydrogenase as a selection criterion for ipili- mumab treatment in metastatic melanoma","volume":"63","author":"Kelderman","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.clim.2020.108395_bb0165","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx225","article-title":"ESMO guidelines committee: management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clim.2020.108395_bb0170","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2020.108395_bb0175","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","article-title":"Prevalence of immune- related systemic adverse events in patients treated with anti- programmed cell death 1\/anti-programmed cell death-ligand 1 agents: a single-Centre pharmacovigilance database analysis","volume":"82","author":"Le Burel","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.clim.2020.108395_bb0180","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2019-216109","article-title":"Immune checkpoint inhibitor- induced inflammatory arthritis persists after immunotherapy cessation","volume":"79","author":"Braaten","year":"2020","journal-title":"Ann. Rheum.Dis."},{"key":"10.1016\/j.clim.2020.108395_bb0185","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"FHU-ACRONIM rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-Centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann.Rheum.Dis."},{"key":"10.1016\/j.clim.2020.108395_bb0190","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.clim.2020.108395_bb0195","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jbspin.2016.01.007","article-title":"Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma","volume":"84","author":"Garel","year":"2017","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.clim.2020.108395_bb0200","first-page":"1192","article-title":"Immune checkpoint inhibitors and inflammatory myopathies: data from the US food and drug administration adverse event reporting system","volume":"69","author":"Pundole","year":"2017","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2020.108395_bb0205","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/CJI.0000000000000196","article-title":"PD-1 inhibitorassociated myopathies: emerging immune-mediated myopathies","volume":"41","author":"Liewluck","year":"2018","journal-title":"J. Immunother."},{"key":"10.1016\/j.clim.2020.108395_bb0210","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","article-title":"Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade","volume":"151","author":"Sheik Ali","year":"2015","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.clim.2020.108395_bb0215","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2169\/internalmedicine.9381-17","article-title":"Advanced lung adenocarcinoma with nivolumab-associated dermatomyositis","volume":"57","author":"Kudo","year":"2018","journal-title":"Intern. Med."},{"key":"10.1016\/j.clim.2020.108395_bb0220","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune checkpoint inhibitor-associated myositis","volume":"138","author":"Anquetil","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.clim.2020.108395_bb0225","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clim.2020.108395_bb0230","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ekir.2018.10.017","article-title":"Immune check point inhibitor associated glomerulonephritis","volume":"4","author":"Ashour","year":"2018","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.clim.2020.108395_bb0235","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2169\/internalmedicine.9814-17","article-title":"IgA nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma","volume":"57","author":"Kishi","year":"2018","journal-title":"Intern. Med."},{"key":"10.1016\/j.clim.2020.108395_bb0240","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12882-016-0408-2","article-title":"Nivolumab-associated acute glomerulonephritis: a case report and literature review","volume":"17","author":"Jung","year":"2016","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.clim.2020.108395_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-centerexperience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.clim.2020.108395_bb0250","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/rheumatology\/kew063","article-title":"Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition","volume":"55","author":"van den Brom","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.clim.2020.108395_bb0255","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1016\/j.jtho.2017.03.011","article-title":"Antineutrophil cytoplasmic antibody-associated rapid progressive glomerulonephritis after pembrolizumab treatment in thymic epithelial tumor: a case report","volume":"12","author":"Heo","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.clim.2020.108395_bb0260","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1053\/j.ajkd.2019.04.016","article-title":"Renal vasculitis and pauci-immune glomerulonephritis associated with immune checkpoint inhibitors","volume":"74","author":"Gallan","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.clim.2020.108395_bb0265","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/art.40745","article-title":"Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients","volume":"71","author":"Richter","year":"2019","journal-title":"Arthr. Rheumatol"},{"key":"10.1016\/j.clim.2020.108395_bb0270","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/cup.13273","article-title":"Scleroderma-like skin changes induced by checkpoint inhibitor therapy","volume":"45","author":"Tjarks","year":"2018","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.clim.2020.108395_bb0275","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.mayocp.2017.03.016","article-title":"Scleroderma induced by pembrolizumab: a case series","volume":"92","author":"Barbosa","year":"2017","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.clim.2020.108395_bb0280","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/2326-6066.CIR-15-0186","article-title":"Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma","volume":"4","author":"Khoja","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.clim.2020.108395_bb0285","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez297","article-title":"Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy","volume":"58","author":"Abdel-Wahab","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.clim.2020.108395_bb0290","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/annrheumdis-2019-216510","article-title":"Chronic inflammatory arthritis following checkpoint inhibitor therapy for cancer: game changing implications","volume":"79","author":"Calabrese","year":"2020","journal-title":"Ann.Rheum.Dis."},{"key":"10.1016\/j.clim.2020.108395_bb0295","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Bingham CO3rd.\u202f: Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2020.108395_bb0300","doi-asserted-by":"crossref","first-page":"106.123","DOI":"10.1111\/imr.12832","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis as a model of autoimmune arthritis","volume":"294","author":"Cappelli","year":"2020","journal-title":"Immunol.Rev."},{"key":"10.1016\/j.clim.2020.108395_bb0305","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.clim.2020.108395_bb0310","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2217\/imt-2016-0048","article-title":"Progress and opportunities for immune therapeutics in osteosarcoma","volume":"8","author":"Lettieri","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.clim.2020.108395_bb0315","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti- PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clim.2020.108395_bb0320","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non- small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2020.108395_bb0325","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/L18-0209","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease","volume":"169","author":"Abdel-Wahab","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.clim.2020.108395_bb0330","series-title":"EMA\/CHMP\/917551\/2019","author":"Abatacept","year":"2019"},{"key":"10.1016\/j.clim.2020.108395_bb0335","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/art.27500","article-title":"The programmed death 1\/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis","volume":"62","author":"Raptopoulou","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2020.108395_bb0340","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00296-009-1249-0","article-title":"The effects of PD-LIg on collagen-induced arthritis","volume":"31","author":"Wang","year":"2011","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.clim.2020.108395_bb0345","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/gutjnl-2014-307311","article-title":"Protective effects of fc-fused PD-L1 on two different animal models of colitis","volume":"64","author":"Song","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.clim.2020.108395_bb0350","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.3389\/fimmu.2018.02306","article-title":"Immune checkpoints as therapeutic targets in autoimmunity","volume":"9","author":"Paluch","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2020.108395_bb0355","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1084\/jem.20100466","article-title":"PD-1 and LAG- 3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice","volume":"208","author":"Okazaki","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2020.108395_bb0360","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1097\/TP.0000000000001379","article-title":"Impact of immune-modulatory drugs on treg","volume":"100","author":"Furukawa","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.clim.2020.108395_bb0365","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune- related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2020.108395_bb0370","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez536","article-title":"Management of rheumatic complications of immune checkpoint inhibitor therapy an oncological perspective","volume":"58","author":"Steven","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.clim.2020.108395_bb0375","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jemermed.2018.07.005","article-title":"Management of immune checkpoint inhibitor toxicities: a review and clinical guideline for emergency physicians","volume":"55","author":"Hryniewicki","year":"2018","journal-title":"J. Emergency Med."},{"key":"10.1016\/j.clim.2020.108395_bb0380","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.clim.2020.108395_bb0385","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1038\/s41467-017-02358-7","article-title":"TNF blockade overcomes resistance to anti-PD-1 in experimental melanoma","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.clim.2020.108395_bb0390","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/acr.23467","article-title":"Arthritis after cancer immunotherapy: symptom duration and treatment response","volume":"71","author":"Smith","year":"2019","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.clim.2020.108395_bb0395","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1136\/annrheumdis-2017-211560","article-title":"Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series","volume":"76","author":"Kim","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2020.108395_bb0400","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2020.108395_bb0405","article-title":"The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity","author":"Schnell","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.clim.2020.108395_bb0410","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor- associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"New Eng. J. Med."},{"key":"10.1016\/j.clim.2020.108395_bb0415","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1172\/JCI131194","article-title":"Time to dissect the autoimmune etiology of cancer antibody immunotherapy","volume":"130","author":"Dougan","year":"2020","journal-title":"J.Clin.Invest."},{"key":"10.1016\/j.clim.2020.108395_bb0420","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00262-017-1962-6","article-title":"Vedolizumab treatment for immune checkpoint inhibitor induced enterocolitis","volume":"66","author":"Bergqvist","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.clim.2020.108395_bb0425","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3389\/fimmu.2017.01547","article-title":"Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract","volume":"8","author":"Dougan","year":"2017","journal-title":"Front. Immunol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661620301583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661620301583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:00:29Z","timestamp":1761494429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661620301583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":85,"alternative-id":["S1521661620301583"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2020.108395","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2020.108395","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108395"}}